{"url_path":"/sec/cntb/8-k/2026-05-12/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1835268/0001835268-26-000019-index.html","accession_number":"0001835268-26-000019","cik":"0001835268","ticker":"CNTB","issuer_name":"Connect Biopharma Holdings Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1835268/0001835268-26-000019-index.html","primary_entity_key":"0001835268","primary_entity_name":"Connect Biopharma Holdings Ltd"},"word_count":292,"has_tables":true,"body_markdown":"cntb-20260512\n0001835268false00018352682026-05-122026-05-12\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n________________________________________\n\nFORM 8-K\n\n________________________________________\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): May 12, 2026\n\n________________________________________\n\nConnect Biopharma Holdings Limited\n\n(Exact name of Registrant as Specified in Its Charter)\n\n________________________________________\n\nCayman Islands001-40212Not Applicable\n\n(State or Other Jurisdiction\nof Incorporation)(Commission File Number)(IRS Employer\nIdentification No.)\n\n3580 Carmel Mountain Road, Suite 200\n\nSan Diego, California\n92130\n\n(Address of Principal Executive Offices)(Zip Code)\n\nRegistrant’s Telephone Number, Including Area Code: (877) 245-2787\n\n________________________________________\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\noWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\noSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\noPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\noPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading\nSymbol(s)Name of each exchange on which registered\n\nOrdinary Shares, par value $0.000174 per ShareCNTBThe Nasdaq Global Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\nEmerging growth company ☒\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o"}